agilon health, inc.

Effective November 3, 2026, the Board of Directors (the “Board”) of the Company approved the following changes to the titles of the Company’s executive officers:

•Tim O’Rourke from Chief Executive Officer and President to Chief Executive Officer;

•Benjamin Shaker, from Chief Markets Officer to President; and

•Denise Zamore, from Chief Legal Officer and Corporate Secretary to Chief Legal and People Officer and Corporate Secretary.

Mr. O’Rourke remains the Company’s sole principal executive officer.

In connection with the title changes, the Compensation and Human Capital Committee of the Board approved increases to the base salaries of Mr. Shaker and Ms. Zamore, effective November 3, 2026. Mr. Shaker’s base salary was increased from $464,000 to $575,000 and Ms. Zamore’s base salary was increased from $437,500 to $500,000. Target annual bonus opportunities, expressed as a percentage of base salary, remain unchanged, so that target bonus amounts increase proportionally with base salary.

The Company expects to enter into amendments to the employment agreements of each of Messrs. O’Rourke and Shaker and Ms. Zamore to reflect each executive’s new title and, as applicable, base salary.

Insider Trading Arrangements and Policies

During the three months ended September 30, 2026, the following officers of the Company (as defined in Rule 16a-1(f) under the Exchange Act) adopted trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (each, a “Rule 10b5-1 Plan”):

•On August 12, 2026, Timothy Gertsch, the Company’s Chief Accounting Officer, adopted a Rule 10b5-1 Plan covering up to 11,040 shares of the Company’s common stock. The Rule 10b5-1 Plan provides for sales beginning no earlier than November 13, 2026, and is scheduled to terminate on December 31, 2027, subject to earlier termination in accordance with its terms.

•On August 17, 2026, Benjamin Shaker, the Company’s then Chief Markets Officer, adopted a Rule 10b5-1 Plan covering up to 46,089 shares of the Company’s common stock and 10,293 options to purchase the Company’s common stock. The Rule 10b5-1 Plan provides for sales beginning no earlier than December 16, 2026, and is scheduled to terminate on September 16, 2027, subject to earlier termination in accordance with its terms.

•On August 21, 2026, Denise Zamore, the Company’s then Chief Legal Officer and Corporate Secretary, adopted a Rule 10b5-1 Plan covering up to 2,533 shares of the Company’s common stock and 1,600 options to purchase the Company’s common stock. The Rule 10b5-1 Plan provides for sales beginning no earlier than November 27, 2026, and is scheduled to terminate on August 16, 2027, subject to earlier termination in accordance with its terms.